Breaking News

Vince Adds GI Capabilities

By Gil Roth | August 20, 2013

Endoscopy suite adds to early phase offerings

Vince & Associates Clinical Research (VACR) has expanded its capabilities in the gastrointestinal (GI) therapeutic area with the addition of a dedicated endoscopy suite at its Clinical Pharmacology Unit.

Dr. Brad Vince, chief executive officer and medical director of Vince & Associates, commented, “This investment reaffirms our dedication to providing research expertise in response to increasing demand for conducting clinical research in patient populations during early development, which often requires more specialized techniques.”

The suite is equipped with advanced and minimally invasive video endoscopy technology from Olympus EndoTherapy. Procedures can be viewed remotely on a large screen and documented by video or still photography. The suite includes two sources of suction as well as resuscitation and medication stations to address patient safety and equipment is maintained at the purpose built disinfection station.

In addition to creating the Endoscopy Suite, VACR has reached out to Summit Gastroenterology for its medical expertise to complement the new research capabilities. Summit's board-certified gastroenterologists have been asked to join the VACR team as investigators, bringing significant clinical expertise as GI specialists.

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials